BayWa's Restructuring Hangs on a Knife-Edge as Legal and Financial Deadlines Collide

German trader BayWa faces a critical week of bank negotiations and a looming payment deadline. Its €4B restructuring is derailed by a failed energy unit sale and growing legal scrutiny.

A critical week of bank negotiations and a looming payment deadline are set to define the immediate future of German agricultural trader BayWa. The company faces a dual challenge: securing fresh capital while battling a growing wave of legal scrutiny that complicates its multi-billion euro restructuring plan.

By April 30, the company expects to receive a €45 million payment from the sale of its grain subsidiary Cefetra, supplemented by approximately €62 million from repaid shareholder loans. While this cash injection is welcome, its primary impact is on the balance sheet. The deconsolidation of Cefetra, combined with using the funds for debt repayment, is projected to reduce the group's bank debt by over €600 million.

This provides only minor relief against a far larger structural deficit. BayWa's overarching divestment target stands at four billion euros by 2028. To date, transactions have secured just €1.3 billion. The failure of a planned partial sale of its renewable energy unit, BayWa r.e., has blown a €2.7 billion hole in the company's recovery blueprint.

The collapse of that deal stems from a policy shift in a key market. The US "One Big Beautiful Bill Act" significantly cut subsidies for renewable energy, undermining the attractiveness of projects sold by BayWa r.e., which moved over 530 megawatts of project capacity there in 2024. The fallout is direct: the 2026 annual forecast has been scrapped and the EBITDA target for 2027 has been lowered to around €140 million. Management is now forced to revise the entire restructuring concept.

Simultaneously, the company is navigating escalating legal troubles. Germany's financial watchdog, BaFin, has formally criticized the 2023 management report for omitting essential details on a billion-euro loan and refinancing risks for a bond. Law firm TILP is preparing shareholder damage claims based on this finding. In a separate development, the Munich I public prosecutor's office is investigating former executives, including ex-CEO Marcus Pöllinger, on suspicion of breach of trust. All accused are presumed innocent. Proceedings are also underway against auditor PwC, from whom BayWa will withdraw its mandate starting in 2026 while assessing its own claims for damages.

Amid this turmoil, the spotlight turns to the next potential asset sale. Goldman Sachs has been mandated to find a buyer for BayWa's 74% stake in New Zealand fruit trader T&G Global. The unit, which posted revenue of $1.3 billion and returned to net profit in 2024, is seen as a solid business. However, analysts anticipate proceeds of only about €300 million—a sum deemed insufficient to bridge the funding gap. The sales process is further complicated by an Asian minority shareholder holding nearly 20% of T&G's shares.

The entire restructuring effort now hinges on the consent of two key banks. If DZ Bank and HVB refuse to extend their standstill agreement until autumn 2026, the StaRUG restructuring plan finalized in May 2025 loses its legal foundation. This buffer is crucial for management to conduct the T&G sale without acute liquidity pressure.

Investors are reflecting the profound uncertainty. While shares gained 6.46% on Friday to close at €14.00, they remain down roughly 21% for the year and trade more than 17% below their 200-day moving average. The market awaits a decisive turn, but audited group financials for 2025 are not expected until the fourth quarter of 2026. Until then, BayWa's fate will be determined not on the trading floor, but in bank meeting rooms and courtrooms.